The Prognostic Values of the Insulin-Like Growth Factor Binding Protein Family in Ovarian Cancer

Table 5

The prognostic value of the IGFBP5 mRNA expression in ovarian cancer.

	Overall survival			Progression-free survival
	Cases	HR (95% CI)	value	Cases	HR (95% CI)	value
Histology
All cancer patients	1656	1.28 (1.12−1.46)	0.00034	1435	1.28 (1.12−1.46)	0.00025
Serous cancer patients	1207	1.19 (1.01−1.4)	0.043	1104	0.92 (0.8−1.06)	0.25
Endometrioid cancer patients	37	6.8 (0.76−60.94)	0.047	51	1.95 (0.77−4.96)	0.15
Pathological grades
I	56	1.43 (0.54−3.78)	0.47	37	2.67 (0.87−8.23)	0.075
II	324	1.5 (1.07−2.12)	0.018	256	1.57 (1.15−2.15)	0.004
III	1015	1.08 (0.91−1.29)	0.37	837	0.83 (0.7−0.98)	0.026
Clinical stages
I and II	135	2.56 (1.07−6.14)	0.029	163	2.08 (1.15−3.77)	0.014
III and IV	1220	1.13 (0.96−1.32)	0.14	1081	0.9 (0.79−1.04)	0.16
Chemotherapy
Contains platin	1409	1.27 (1.09−1.47)	0.0017	1259	1.27 (1.1−1.47)	0.00099
Contains taxol	793	1.37 (1.12−1.67)	0.002	715	1.2 (0.99−1.47)	0.063
Contains taxol+platin	776	1.4 (1.14−1.71)	0.0012	698	1.21 (1.01−1.46)	0.04

.